Stealth BioTherapeutics announces presentation of Phase 1 trial data on Bevemipretide drops targeting dry AMD at the upcoming ARVO 2026.

i-Lumen Scientific has received FDA Investigational Device Exemption to initiate U.S. enrollment in the i-SIGHT2 clinical study for treating dry AMD, a major vision loss cause.

i-Lumen Scientific's non-invasive method for treating dry AMD receives FDA clearance to begin patient recruitment in the U.S. for an ongoing clinical study.

Avirmax Biopharma is set to make a significant impact at the 2025 ARVO meeting with multiple presentations focused on ocular gene therapy advancements through its proprietary technologies.